(Reuters) -Merck and Japan-based Daiichi Sankyo said on Thursday they have withdrawn the U.S. application for an experimental lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like “guided missiles”.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
